Louis Moore Bacon's CBIO Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 25,000 shares of Crescent Biopharma, Inc. (CBIO) worth $459,250, representing 0.01% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Louis Moore Bacon has initiated a new position in CBIO, representing a fresh investment thesis on this company.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Crescent Biopharma (CBIO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Crescent Biopharma (CBIO) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +25,000 | New Buy | 25,000 | $11.86 |
Louis Moore Bacon's Crescent Biopharma Investment FAQs
Louis Moore Bacon first purchased Crescent Biopharma, Inc. (CBIO) in Q4 2025, acquiring 25,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Crescent Biopharma, Inc. (CBIO) for 2 quarters since Q4 2025.
Louis Moore Bacon's largest addition to Crescent Biopharma, Inc. (CBIO) was in Q4 2025, adding 25,000 shares worth $296,500.
According to the latest 13F filing for Q1 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 25,000 shares of Crescent Biopharma, Inc. (CBIO), valued at approximately $459,250.
As of the Q1 2026 filing, Crescent Biopharma, Inc. (CBIO) represents approximately 0.01% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Crescent Biopharma, Inc. (CBIO) was 25,000 shares, as reported at the end of Q4 2025.